For research use only, not for therapeutic use.
Ganetespib（Cat No.:I013970）is a potent, second-generation inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone essential for the stability and function of various oncogenic proteins. By inhibiting Hsp90, Ganetespib promotes the degradation of client proteins, disrupting critical signaling pathways involved in cancer cell growth and survival. It has shown broad antitumor activity in preclinical and clinical studies, particularly in cancers like lung, breast, and colorectal cancer. With improved potency and reduced toxicity compared to first-generation Hsp90 inhibitors, Ganetespib is a promising candidate in targeted cancer therapies.
| Catalog Number | I013970 |
| CAS Number | 888216-25-9 |
| Molecular Formula | C₂₀H₂₀N₄O₃ |
| Purity | ≥95% |
| Target | HSP |
| Solubility | DMSO: ≥ 32 mg/mL |
| IUPAC Name | 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one |
| InChI | InChI=1S/C20H20N4O3/c1-11(2)14-9-15(18(26)10-17(14)25)19-21-22-20(27)24(19)13-4-5-16-12(8-13)6-7-23(16)3/h4-11,25-26H,1-3H3,(H,22,27) |
| InChIKey | RVAQIUULWULRNW-UHFFFAOYSA-N |
| SMILES | CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O |
| Reference | [1]. Shimamura T, et al. Ganetespib (STA-9090), a Non-Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Jul 17.<br>[2]. Ying W, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012 Feb;11(2):475-84.<br>[3]. London CA, et al. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.<br>PLoS One. 2011;6(11):e27018.<br>[4]. Proia DA, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011 Apr 14;6(4):e18552. |
